Free Trial

PetVivo (PETV) Competitors

PetVivo logo
$0.81 +0.03 (+3.42%)
As of 08/15/2025 02:53 PM Eastern

PETV vs. HYPR, NVNO, APYX, NTRB, VANI, CTSO, LUNG, TELA, RBOT, and SPAI

Should you be buying PetVivo stock or one of its competitors? The main competitors of PetVivo include Hyperfine (HYPR), enVVeno Medical (NVNO), Apyx Medical (APYX), Nutriband (NTRB), Vivani Medical (VANI), Cytosorbents (CTSO), Pulmonx (LUNG), TELA Bio (TELA), Vicarious Surgical (RBOT), and Safe Pro Group (SPAI). These companies are all part of the "medical equipment" industry.

PetVivo vs. Its Competitors

Hyperfine (NASDAQ:HYPR) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 31.0% of Hyperfine shares are held by insiders. Comparatively, 10.8% of PetVivo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PetVivo has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperfine$10.80M10.02-$40.72M-$0.52-2.67
PetVivo$1.05M21.64-$10.95M-$0.40-2.03

Hyperfine has a net margin of -364.54% compared to PetVivo's net margin of -902.82%. Hyperfine's return on equity of -84.82% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperfine-364.54% -84.82% -69.39%
PetVivo -902.82%-4,813.07%-281.78%

Hyperfine has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, PetVivo has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

In the previous week, Hyperfine had 13 more articles in the media than PetVivo. MarketBeat recorded 16 mentions for Hyperfine and 3 mentions for PetVivo. Hyperfine's average media sentiment score of 0.44 beat PetVivo's score of 0.00 indicating that Hyperfine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperfine
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
PetVivo
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hyperfine presently has a consensus price target of $1.28, indicating a potential downside of 7.67%. Given Hyperfine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Hyperfine is more favorable than PetVivo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
PetVivo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Hyperfine beats PetVivo on 11 of the 16 factors compared between the two stocks.

Get PetVivo News Delivered to You Automatically

Sign up to receive the latest news and ratings for PETV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PETV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PETV vs. The Competition

MetricPetVivoSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$21.89M$72.63M$5.72B$9.79B
Dividend YieldN/AN/A3.91%4.13%
P/E Ratio-1.8010.3231.1425.06
Price / Sales21.6493.82416.7890.80
Price / CashN/A18.4136.7858.67
Price / Book-27.047.439.086.18
Net Income-$10.95M-$25.86M$3.26B$265.11M
7 Day Performance-6.75%0.95%7.39%4.22%
1 Month Performance3.99%1.38%4.22%0.77%
1 Year Performance35.18%52.73%30.30%24.69%

PetVivo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PETV
PetVivo
N/A$0.81
+3.4%
N/A+62.2%$21.89M$1.05M-1.8020News Coverage
HYPR
Hyperfine
1.6369 of 5 stars
$1.20
-7.7%
$1.06
-11.7%
+31.1%$93.40M$12.89M-2.22190News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
NVNO
enVVeno Medical
0.8084 of 5 stars
$4.58
+1.3%
N/A-6.7%$88.17MN/A-3.8230News Coverage
APYX
Apyx Medical
1.8437 of 5 stars
$2.24
+0.4%
N/A+60.0%$84.72M$48.10M-4.98270News Coverage
Gap Up
NTRB
Nutriband
3.293 of 5 stars
$6.80
-0.7%
$13.00
+91.2%
+16.9%$75.82M$2.14M-7.5610Short Interest ↓
VANI
Vivani Medical
2.1757 of 5 stars
$1.27
+0.8%
$4.00
+215.0%
-2.3%$75.24MN/A-2.9520News Coverage
Earnings Report
CTSO
Cytosorbents
2.1496 of 5 stars
$1.06
-11.7%
$5.50
+418.9%
+11.5%$66.53M$35.60M-6.24220News Coverage
Analyst Revision
Gap Down
LUNG
Pulmonx
4.2754 of 5 stars
$1.59
+2.6%
$7.66
+382.0%
-76.3%$64.79M$83.79M-1.11250
TELA
TELA Bio
2.7483 of 5 stars
$1.60
-14.0%
$7.25
+353.1%
-49.2%$63.30M$69.30M-1.13120Earnings Report
RBOT
Vicarious Surgical
0.8063 of 5 stars
$10.31
+12.0%
$8.50
-17.5%
+16.4%$61.11MN/A-0.99210News Coverage
Earnings Report
Analyst Forecast
SPAI
Safe Pro Group
0.717 of 5 stars
$4.01
+3.9%
$8.00
+99.5%
N/A$60.83M$2.17M-4.9511Earnings Report
Gap Down

Related Companies and Tools


This page (NASDAQ:PETV) was last updated on 8/17/2025 by MarketBeat.com Staff
From Our Partners